Question

MOA of Teduglutide in short bowel syndrome?

• A. GLP-2 inhibitor
• B. HT1a inhibitor
• C. GLP-1 analogs
• D. C-peptide analogs

Answer 1

The Correct Option is A

Mechanism of Action of Teduglutide in Short Bowel Syndrome:

Teduglutide is classified as a GLP-2 analog. GLP-2, or Glucagon-Like Peptide-2, plays a vital role in intestinal growth and function. Unlike a GLP-2 inhibitor, Teduglutide mimics the activity of GLP-2, thereby offering therapeutic benefits in short bowel syndrome (SBS). Here's how it works:

• Teduglutide binds to the GLP-2 receptors on the intestinal cells.
• This binding stimulates the growth of the intestinal mucosa, which increases the absorptive surface area of the intestine.
• It enhances the intestinal barrier function, which reduces bacterial translocation.
• The actions result in improved nutrient absorption and reduced need for parenteral nutrition in patients with SBS.

The option GLP-2 inhibitor is incorrect in the context of Teduglutide's mechanism, as it enhances rather than inhibits the effects of GLP-2.